Tisagenlecleucel: CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma.
Expert Opin Biol Ther
; 23(9): 869-876, 2023.
Article
em En
| MEDLINE
| ID: mdl-37599463
ABSTRACT
INTRODUCTION:
Tisagenlecleucel (tisa-cel) is an anti CD19 CAR-T therapy that has demonstrated clinical activity in R/R large B-cell lymphoma and R/R B-cell acute lymphoblastic leukemia. It showed particularly high efficacy in R/R follicular lymphoma (FL) with a manageable toxicity profile. The pivotal ELARA study in R/R FL confirmed these findings and led to the FDA approval of tisa-cel in R/R FL after two lines of systemic therapies. AREAS COVERED We start with an introduction of FL and the current treatment landscape with emphasis on the R/R setting. We review the role of CAR-T in R/R FL with focus on currently available products. We describe the ELARA study at a high level to give a perspective of the patient population that was treated. Finally, we discuss aspects related to product selection and whether bispecific antibodies will challenge the role of CAR-T in FL given their similar efficacy. EXPERT OPINION Tisa-cel is a highly effective therapy for heavily pretreated R/R FL with a toxicity profile that is low grade and manageable. Durable remissions (including high-risk patients) are seen in the pivotal ELARA study. Clinicians should consider early referral of R/R FL patients for assessment and discussion.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Linfoma Folicular
/
Linfoma Difuso de Grandes Células B
/
Receptores de Antígenos Quiméricos
Limite:
Adult
/
Humans
Idioma:
En
Revista:
Expert Opin Biol Ther
Ano de publicação:
2023
Tipo de documento:
Article